<!--।। श्री ।।-->
<!DOCTYPE html>
<html lang="en-IN">
	<head>
		<meta charset="UTF-8" />
		<meta name="viewport" content="width=device-width, initial-scale=1" />

		<title>Patient Care Pathway</title>
		<meta name="theme-color" content="#d1325d" />
		<link
			rel="icon"
			href="data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 100 100'%3E%3Crect x='0' y='0' width='100' height='100' fill='%23fff'/%3E%3Ctext x='-.06em' y='.97em' font-size='80'%3E🔴%3C/text%3E%3C/svg%3E"
		/>

		<link rel="preconnect" href="https://fonts.googleapis.com" />
		<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
		<link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Manrope:wght@200;300;400;500;600;700;800&display=swap" />

		<link rel="stylesheet" href="/style.css" />
		<script defer src="/script.js"></script>
	</head>
	<body>
		<svg xmlns="http://www.w3.org/2000/svg" style="display: none">
			<symbol viewBox="0 0 24 24" id="plus">
				<path d="M12 6.34315V17.6569M6.34314 12H17.6568" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" />
			</symbol>
		</svg>

		<header>
			<span>Chronic Heart Failure –</span>
			<h1>Patient Care Pathway</h1>
		</header>
		<main>
			<section id="section-1" class="← ↓ ↙">
				<img src="images/icon-1.svg" />
				<content>
					<h2>PATIENT WITH SUSPECTED HF</h2>
					<fixed-grid-1>
						<flex>
							<i class="pink check"></i>
							<p>Shows typical signs and symptoms - breathlessness, fatigue, and ankle swelling</p>
						</flex>
						<flex>
							<i class="pink check"></i>
							<p>Presence of risk factors</p>
						</flex>
						<flex>
							<i class="pink check"></i>
							<p>Abnormal ECG</p>
						</flex>
					</fixed-grid-1>
				</content>
			</section>

			<section id="section-2" class="↑ → ↓ ↗ ↘">
				<wrap>
					<h2><span>1</span>INITIAL DIAGNOSTIC TESTS</h2>
					<fixed-grid-2>
						<content>
							<strong>BNP &lt;35 pg/mL Or NT-proBNP &lt;125 pg/mL Or MR-proANP &lt;40 pmol/L</strong>
							<ul>
								<li>HF unlikely<i class="pink wrong"></i></li>
								<li>Consider other diagnoses</li>
							</ul>

							<popup>
								<button class="popup-btn">
									Want to know more?
									<svg class="icon-icon"><use xlink:href="#plus" /></svg>
								</button>
								<popup-modal>
									<ul>
										<li>
											Plasma concentrations of NPs are recommended as initial diagnostic tests in patients with signs and symptoms suggestive of HF
											to rule out the diagnosis.
										</li>
										<li>Class I recommendation (recommended or indicated) for use of NPs in diagnosis of chronic HF.</li>
										<li>
											Elevated NP concentrations support a <strong>diagnosis of HF</strong>, are useful for <strong>prognostication</strong>, and may
											<strong>guide further cardiac investigation</strong>.
										</li>
									</ul>
								</popup-modal>
							</popup>
						</content>
						<content>
							<strong>NT-proBNP ≥ 125 pg/mL Or<br />BNP ≥ 35 pg/mL</strong>
							<ul>
								<li>May be HF<i class="green check"></i></li>
								<li>Proceed to echocardiography</li>
							</ul>

							<popup>
								<button class="popup-btn">
									Caveats to Consider
									<svg class="icon-icon"><use xlink:href="#plus" /></svg>
								</button>
								<popup-modal>
									<ul>
										<li>Alternative causes of an elevated NP can include AF, increasing age, and acute or chronic kidney disease.</li>
										<li>NP can be disproportionately low in obese patients.</li>
									</ul>
								</popup-modal>
							</popup>
						</content>
					</fixed-grid-2>
				</wrap>
				<img src="images/icon-2.svg" />
			</section>

			<section id="section-3" class="↑ ← ↓ ↖ ↙">
				<img src="images/icon-3.svg" />
				<fixed-grid-3>
					<h2><span>2</span>ECHOCARDIOGRAPHY</h2>

					<popup>
						<button class="popup-btn">
							Want to know more?
							<svg class="icon-icon"><use xlink:href="#plus" /></svg>
						</button>
						<popup-modal>
							<strong>ECHOCARDIOGRAPHY should be conducted if:</strong>
							<ul>
								<li>Elevated NPs concentrations</li>
								<li>or HF strongly suspected</li>
								<li>or NT-proBNP/BNP unavailable</li>
							</ul>
						</popup-modal>
					</popup>

					<content>
						<strong>If normal echocardiography</strong>
						<ul>
							<li>HF unlikely<i class="pink wrong"></i></li>
							<li>Consider other diagnoses</li>
						</ul>
					</content>
					<flex id="custom-1" class="col">
						<content>
							<strong>If abnormal echocardiography</strong>
							<ul>
								<li>HF is confirmed<i class="green check"></i></li>
								<li>Define HF phenotype</li>
							</ul>
						</content>
						<i class="arrow-down"></i>
						<content id="custom-2">LVEF</content>
						<flex id="custom-3">
							<content>
								≤40%
								<i class="arrow-down"></i>
								HFrEF
							</content>
							<content>
								41-49%
								<i class="arrow-down"></i>
								HFmrEF
							</content>
							<content>
								≥50%
								<i class="arrow-down"></i>
								HFpEF
							</content>
						</flex>
					</flex>
				</fixed-grid-3>
			</section>

			<section id="section-4" class="↑ → ↗">
				<flex class="col">
					<h2><span>3</span>TREATMENT</h2>
					<flex id="custom-3">
						<content>
							HFrEF
							<i class="arrow-down"></i>
						</content>
						<content>
							HFmrEF
							<i class="arrow-down"></i>
						</content>
						<content>
							HFpEF
							<i class="arrow-down"></i>
						</content>
					</flex>
					<content id="custom-2">Guideline Recommended Pharmacological Treatment</content>

					<popup>
						<button class="popup-btn">
							Want to know more?
							<svg class="icon-icon"><use xlink:href="#plus" /></svg>
						</button>
						<popup-modal>
							<flex>
								<div>
									<strong>Treatment for HFrEF and NYHA class II symptoms or worse:</strong>
									<ul>
										<li>
											Angiotensin receptor neprilysin inhibitor (ARNI) as a replacement for angiotensin-converting enzyme (ACE) inhibitors - Class I
											recommendations.
										</li>
										<li>Addition of SGLT-2 inhibitors (dapagliflozin or empagliflozin) - Class I recommendations.</li>
									</ul>
								</div>
								<hr />
								<div>
									<strong>Treatment for HFmrEF</strong>
									<ul>
										<li>Diuretics to relieve congestion.</li>
										<li>
											ACE inhibitors/angiotensin-receptor blockers/ARNIs/beta-blockers/mineralocorticoid receptor antagonists may be considered as
											additional therapy to reduce mortality and hospitalization (Class IIa recommendation).
										</li>
									</ul>
								</div>
								<hr />
								<div>
									<strong>Treatment for HFpEF</strong>
									<ul>
										<li>Diagnosis and treatment of contributing factors (hypertension, kidney disease, etc.).</li>
										<li>Use of diuretics.</li>
										<li>Evidence based therapies proven with reducing the major heart failure outcomes.</li>
									</ul>
								</div>
							</flex>
						</popup-modal>
					</popup>
				</flex>
				<img src="images/icon-4.svg" />
			</section>
		</main>
	</body>
</html>
